(Q33943526)

30 July 2017

1 reference

title

Clinical application of 5alpha-reductase inhibitors (English)

1 reference

30 July 2017

Cilotti A

1

1 reference

30 July 2017

Danza G

series ordinal

2

1 reference

30 July 2017

Serio M

series ordinal

3

1 reference

30 July 2017

publication date

1 March 2001

1 reference

Journal of Endocrinological Investigation

30 July 2017

published in

1 reference

30 July 2017

volume

24

1 reference

30 July 2017

issue

3

1 reference

30 July 2017

page(s)

199-203

1 reference

Characterization and chromosomal mapping of a human steroid 5 alpha-reductase gene and pseudogene and mapping of the mouse homologue

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03343844

Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343844

Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343844

Brief report: the molecular basis of steroid 5 alpha-reductase deficiency in a large Dominican kindred

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343844

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343844

Azasteroids: structure-activity relationships for inhibition of 5 alpha-reductase and of androgen receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343844

Clinical pharmacokinetics and pharmacodynamics of finasteride

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343844

6-Azasteroids: potent dual inhibitors of human type 1 and 2 steroid 5 alpha-reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343844

6-Azasteroids: structure-activity relationships for inhibition of type 1 and 2 human 5 alpha-reductase and human adrenal 3 beta-hydroxy-delta 5-steroid dehydrogenase/3-keto-delta 5-steroid isomerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343844

Nonsteroidal inhibitors of human type I steroid 5-alpha-reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343844

Effect of Finasteride, a 5α-Reductase Inhibitor on Prostate Tissue Androgens and Prostate-Specific Antigen*

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343844

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343844

Genetic analysis of male pattern baldness and the 5alpha-reductase genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343844

Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343844

Design of the Prostate Cancer Prevention Trial (PCPT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03343844

Effect of a vitamin D3 analogue on keratinocyte growth factor-induced cell proliferation in benign prostate hyperplasia

21 January 2018

1 reference

12 December 2020

Synthesis of benzo[c]quinolizin-3-ones: selective non-steroidal inhibitors of steroid 5 alpha-reductase 1

1 reference

12 December 2020

Azasteroids as inhibitors of rat prostatic 5 alpha-reductase

1 reference

12 December 2020

The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness

1 reference

12 December 2020

Steroid 5 alpha-reductase 2 deficiency

1 reference

12 December 2020

19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2

1 reference

12 December 2020

A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women

1 reference

12 December 2020

5 alpha-reductase expression by prostate cancer cell lines and benign prostatic hyperplasia in vitro

1 reference

12 December 2020

The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group

1 reference

12 December 2020

Synthesis of 8-chloro-benzo[c]quinolizin-3-ones as potent and selective inhibitors of human steroid 5alpha-reductase 1

1 reference

12 December 2020

Immunohistochemical localization of types 1 and 2 5alpha-reductase in human scalp

1 reference

12 December 2020

Predominant expression of 5 alpha-reductase type 1 in pubic skin from normal subjects and hirsute patients

1 reference

12 December 2020

5 alpha-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates--effect of finasteride (Proscar), a 5 alpha-reductase inhibitor

1 reference

12 December 2020

The biochemical and phenotypic characterization of females homozygous for 5 alpha-reductase-2 deficiency

1 reference

12 December 2020

Dual control by androgens and peptide growth factors of prostatic growth in human benign prostatic hyperplasia

1 reference

12 December 2020

Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03343844

1 reference

Dimensions Publication ID

30 July 2017

1012876560

0 references

1 reference